[
  {
    "ts": null,
    "headline": "2 Profitable Stocks to Own for Decades and 1 We Brush Off",
    "summary": "Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.",
    "url": "https://finnhub.io/api/news?id=faf7a9d4b2576367376aeb820144598e659e7fec71daea273d68904271577ac8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762144562,
      "headline": "2 Profitable Stocks to Own for Decades and 1 We Brush Off",
      "id": 137302053,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MCK",
      "source": "Yahoo",
      "summary": "Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.",
      "url": "https://finnhub.io/api/news?id=faf7a9d4b2576367376aeb820144598e659e7fec71daea273d68904271577ac8"
    }
  },
  {
    "ts": null,
    "headline": "How Investors Are Reacting To McKesson (MCK) Securing LYMPHIR’s Distribution Ahead of U.S. Launch",
    "summary": "In October 2025, Citius Oncology announced a distribution services agreement with McKesson, making McKesson an authorized distributor of record for LYMPHIR, a newly FDA-approved immunotherapy for certain cutaneous T-cell lymphoma patients, with national distribution ahead of its planned commercial launch later in the year. This collaboration completes LYMPHIR’s U.S. distribution network through the nation’s three largest pharmaceutical wholesalers, highlighting McKesson’s central role in...",
    "url": "https://finnhub.io/api/news?id=a55bce15f827e1a18b005e49009f268844af0905631a6e89b417a39198381c39",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762135611,
      "headline": "How Investors Are Reacting To McKesson (MCK) Securing LYMPHIR’s Distribution Ahead of U.S. Launch",
      "id": 137303098,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MCK",
      "source": "Yahoo",
      "summary": "In October 2025, Citius Oncology announced a distribution services agreement with McKesson, making McKesson an authorized distributor of record for LYMPHIR, a newly FDA-approved immunotherapy for certain cutaneous T-cell lymphoma patients, with national distribution ahead of its planned commercial launch later in the year. This collaboration completes LYMPHIR’s U.S. distribution network through the nation’s three largest pharmaceutical wholesalers, highlighting McKesson’s central role in...",
      "url": "https://finnhub.io/api/news?id=a55bce15f827e1a18b005e49009f268844af0905631a6e89b417a39198381c39"
    }
  }
]